ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)
New data show systemic delivery of antimiR-23b developed on ARTHEx BOOST-ON™ platform reaches the brain, corrects disease biology, and improves behavior—highlighting potential to address CNS manifestations of DM1 VALENCIA, Spain, July 23, 2026 /PRNewswire/ -- Arthex Biotech, a...
New data show systemic delivery of antimiR-23b developed on ARTHEx BOOST-ON™ platform reaches the brain, corrects disease biology, and improves behavior—highlighting potential to address CNS manifestations of DM1 VALENCIA, Spain, July 23, 2026 /PRNewswire/ -- Arthex Biotech, a...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.